Abbott Laboratories ROE 2012-2026 | ABT
Current and historical return on equity (ROE) values for Abbott Laboratories (ABT) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Abbott Laboratories ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2026-06-30 | $5.43B | $52.13B | 10.41% |
| 2026-03-31 | $6.28B | $51.89B | 12.09% |
| 2025-12-31 | $6.52B | $50.98B | 12.80% |
| 2025-09-30 | $13.98B | $49.77B | 28.09% |
| 2025-06-30 | $13.98B | $46.96B | 29.77% |
| 2025-03-31 | $13.50B | $44.14B | 30.59% |
| 2024-12-31 | $13.40B | $41.63B | 32.19% |
| 2024-09-30 | $5.77B | $39.37B | 14.65% |
| 2024-06-30 | $5.56B | $38.78B | 14.33% |
| 2024-03-31 | $5.63B | $38.24B | 14.72% |
| 2023-12-31 | $5.72B | $37.79B | 15.14% |
| 2023-09-30 | $5.16B | $37.31B | 13.84% |
| 2023-06-30 | $5.16B | $36.86B | 14.00% |
| 2023-03-31 | $5.80B | $36.68B | 15.82% |
| 2022-12-31 | $6.93B | $36.28B | 19.11% |
| 2022-09-30 | $7.89B | $36.06B | 21.88% |
| 2022-06-30 | $8.55B | $35.75B | 23.93% |
| 2022-03-31 | $7.73B | $35.08B | 22.02% |
| 2021-12-31 | $7.07B | $34.62B | 20.42% |
| 2021-09-30 | $7.24B | $33.87B | 21.39% |
| 2021-06-30 | $6.38B | $33.10B | 19.26% |
| 2021-03-31 | $5.72B | $32.30B | 17.72% |
| 2020-12-31 | $4.50B | $31.46B | 14.29% |
| 2020-09-30 | $3.38B | $31.03B | 10.90% |
| 2020-06-30 | $3.11B | $31.14B | 9.99% |
| 2020-03-31 | $3.58B | $31.41B | 11.39% |
| 2019-12-31 | $3.69B | $31.59B | 11.67% |
| 2019-09-30 | $3.29B | $31.44B | 10.47% |
| 2019-06-30 | $2.90B | $31.16B | 9.29% |
| 2019-03-31 | $2.62B | $30.88B | 8.49% |
| 2018-12-31 | $2.37B | $31.00B | 7.64% |
| 2018-09-30 | $0.89B | $31.09B | 2.85% |
| 2018-06-30 | $0.93B | $31.42B | 2.95% |
| 2018-03-31 | $0.48B | $31.68B | 1.50% |
| 2017-12-31 | $0.48B | $31.66B | 1.51% |
| 2017-09-30 | $2.10B | $29.07B | 7.23% |
| 2017-06-30 | $1.17B | $26.24B | 4.46% |
| 2017-03-31 | $1.50B | $23.49B | 6.40% |
| 2016-12-31 | $1.40B | $20.81B | 6.73% |
| 2016-09-30 | $1.37B | $20.97B | 6.53% |
| 2016-06-30 | $2.28B | $21.05B | 10.82% |
| 2016-03-31 | $2.45B | $21.63B | 11.31% |
| 2015-12-31 | $4.42B | $21.92B | 20.18% |
| 2015-09-30 | $4.56B | $21.99B | 20.74% |
| 2015-06-30 | $4.52B | $22.44B | 20.14% |
| 2015-03-31 | $4.20B | $22.58B | 18.60% |
| 2014-12-31 | $2.28B | $22.96B | 9.95% |
| 2014-09-30 | $1.97B | $23.86B | 8.25% |
| 2014-06-30 | $2.40B | $24.06B | 9.96% |
| 2014-03-31 | $2.41B | $23.74B | 10.14% |
| 2013-12-31 | $2.58B | $23.54B | 10.94% |
| 2013-09-30 | $3.04B | $23.93B | 12.70% |
| 2013-06-30 | $4.02B | $24.76B | 16.22% |
| 2013-03-31 | $5.27B | $25.29B | 20.82% |
| 2012-12-31 | $5.96B | $26.01B | 22.93% |
| 2012-09-30 | $6.53B | $25.44B | 25.67% |
| 2012-06-30 | $4.89B | $24.83B | 19.69% |
| 2012-03-31 | $5.11B | $25.31B | 20.18% |
| 2011-12-31 | $4.73B | $25.10B | 18.84% |
| 2011-09-30 | $4.55B | $24.66B | 18.45% |
| 2011-06-30 | $5.14B | $23.86B | 21.54% |
| 2011-03-31 | $4.49B | $22.24B | 20.18% |
| 2010-12-31 | $4.63B | $21.31B | 21.71% |
| 2010-09-30 | $4.73B | $21.42B | 22.06% |
| 2010-06-30 | $5.31B | $21.39B | 24.84% |
| 2010-03-31 | $5.31B | $21.37B | 24.84% |
| 2009-12-31 | $5.75B | $20.62B | 27.87% |
| 2009-09-30 | $5.74B | $19.20B | 29.91% |
| 2009-06-30 | $5.35B | $18.69B | 28.61% |
| 2009-03-31 | $5.38B | $18.45B | 29.17% |
| 2008-12-31 | $4.88B | $18.45B | 26.45% |
| 2008-09-30 | $4.55B | $18.53B | 24.55% |
| 2008-06-30 | $4.18B | $17.59B | 23.76% |
| 2008-03-31 | $3.85B | $16.69B | 23.05% |
| 2007-12-31 | $3.61B | $15.77B | 22.87% |
| 2007-09-30 | $1.93B | $14.83B | 13.00% |
| 2007-06-30 | $1.93B | $14.84B | 12.99% |
| 2007-03-31 | $1.55B | $14.80B | 10.47% |
| 2006-12-31 | $1.72B | $14.83B | 11.58% |
| 2006-09-30 | $3.17B | $14.92B | 21.24% |
| 2006-06-30 | $3.13B | $14.58B | 21.50% |
| 2006-03-31 | $3.40B | $14.38B | 23.64% |
| 2005-12-31 | $3.37B | $14.31B | 23.56% |
| 2005-09-30 | $3.37B | $14.29B | 23.59% |
| 2005-06-30 | $3.49B | $13.96B | 25.03% |
| 2005-03-31 | $3.25B | $13.57B | 23.96% |
| 2004-12-31 | $3.24B | $13.41B | 24.14% |
| 2004-09-30 | $3.21B | $13.09B | 24.48% |
| 2004-06-30 | $3.16B | $12.82B | 24.67% |
| 2004-03-31 | $2.78B | $12.59B | 22.05% |
| 2003-12-31 | $2.75B | $12.05B | 22.85% |
| 2003-09-30 | $2.44B | $11.45B | 21.28% |
| 2003-06-30 | $2.40B | $11.12B | 21.54% |
| 2003-03-31 | $2.74B | $10.62B | 25.81% |
| 2002-12-31 | $2.79B | $10.14B | 27.55% |
| 2002-09-30 | $2.78B | $9.74B | 28.56% |
| 2002-06-30 | $2.69B | $9.27B | 29.04% |
| 2002-03-31 | $2.63B | $8.93B | 29.42% |
| 2001-12-31 | $1.55B | $8.60B | 18.03% |
| 2001-09-30 | $1.69B | $8.48B | 19.93% |
| 2001-06-30 | $1.71B | $8.39B | 20.42% |
| 2001-03-31 | $1.87B | $8.29B | 22.53% |
| 2000-12-31 | $2.79B | $8.24B | 33.82% |
| 2000-09-30 | $2.70B | $7.95B | 33.91% |
| 2000-06-30 | $2.51B | $7.54B | 33.27% |
| 2000-03-31 | $2.47B | $7.10B | 34.72% |
| 1999-12-31 | $2.44B | $6.65B | 36.72% |
| 1999-09-30 | $2.41B | $6.22B | 38.67% |
| 1999-06-30 | $2.47B | $5.90B | 41.92% |
| 1999-03-31 | $2.42B | $5.62B | 43.01% |
| 1998-12-31 | $2.34B | $5.39B | 43.38% |
| 1998-09-30 | $2.28B | $5.21B | 43.70% |
| 1998-06-30 | $2.21B | $5.07B | 43.64% |
| 1998-03-31 | $2.15B | $4.98B | 43.17% |
| 1997-12-31 | $2.10B | $4.91B | 42.68% |
| 1997-09-30 | $2.04B | $4.86B | 41.92% |
| 1997-06-30 | $1.99B | $4.83B | 41.17% |
| 1997-03-31 | $1.94B | $4.76B | 40.71% |
| 1996-12-31 | $1.88B | $4.69B | 40.17% |
| 1996-09-30 | $1.84B | $4.58B | 40.09% |
| 1996-06-30 | $1.80B | $4.47B | 40.20% |
| 1996-03-31 | $1.75B | $4.37B | 40.06% |
| 1995-12-31 | $1.69B | $4.26B | 39.61% |
| 1995-09-30 | $1.65B | $4.18B | 39.43% |
| 1995-06-30 | $1.62B | $4.10B | 39.44% |
| 1995-03-31 | $1.57B | $4.00B | 39.22% |
| 1994-12-31 | $1.52B | $3.90B | 38.86% |
| 1994-09-30 | $1.49B | $3.81B | 38.97% |
| 1994-06-30 | $1.45B | $3.72B | 39.00% |
| 1994-03-31 | $1.42B | $3.64B | 39.00% |
| 1993-12-31 | $1.40B | $3.56B | 39.29% |
| 1993-09-30 | $1.36B | $3.48B | 39.01% |
| 1993-06-30 | $1.32B | $3.42B | 38.62% |
| 1993-03-31 | $1.29B | $3.37B | 38.30% |
| 1992-12-31 | $1.24B | $3.33B | 37.20% |
| 1992-09-30 | $1.21B | $3.29B | 36.58% |
| 1992-06-30 | $1.18B | $3.21B | 36.69% |
| 1992-03-31 | $1.13B | $3.11B | 36.28% |
| 1991-12-31 | $1.09B | $3.03B | 36.00% |
| 1991-09-30 | $1.05B | $2.93B | 35.94% |
| 1991-06-30 | $1.02B | $2.86B | 35.83% |
| 1991-03-31 | $1.00B | $2.80B | 35.51% |
| 1990-12-31 | $0.97B | $2.76B | 35.05% |
| 1990-09-30 | $0.94B | $2.73B | 34.41% |
| 1990-06-30 | $0.91B | $2.71B | 33.70% |
| 1990-03-31 | $0.89B | $2.67B | 33.17% |
| 1989-12-31 | $0.86B | $2.62B | 32.85% |
| 1989-09-30 | $0.83B | $2.55B | 32.47% |
| 1989-06-30 | $0.81B | $2.47B | 32.62% |
| 1989-03-31 | $0.78B | $2.38B | 32.59% |
| 1988-12-31 | $0.75B | $2.29B | 32.79% |
| 1988-09-30 | $0.72B | $2.20B | 32.73% |
| 1988-06-30 | $0.69B | $2.11B | 32.84% |
| 1988-03-31 | $0.66B | $2.02B | 32.77% |
| 1987-12-31 | $0.63B | $1.95B | 32.54% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $178.385B | $44.328B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $119.983B | 16.40 |
| Stryker (SYK) | United States | $108.118B | 20.21 |
| EssilorLuxottica (ESLOY) | France | $79.433B | 0.00 |
| Boston Scientific (BSX) | United States | $65.288B | 14.03 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.930B | 0.00 |
| Medline (MDLN) | United States | $42.846B | 0.00 |
| Agilent Technologies (A) | United States | $41.387B | 24.22 |
| ResMed (RMD) | United States | $32.167B | 19.96 |
| GE HealthCare Technologies (GEHC) | United States | $29.021B | 13.88 |
| Koninklijke Philips (PHG) | Netherlands | $24.651B | 13.13 |
| Terumo (TRUMY) | Japan | $21.625B | 20.65 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.414B | 11.38 |
| Baxter (BAX) | United States | $12.336B | 11.64 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.926B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.854B | 39.71 |
| Demant (WILYY) | Denmark | $9.592B | 0.00 |
| Insulet (PODD) | United States | $9.557B | 23.48 |
| Sunny Optical Technology (SNPTF) | China | $9.142B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.548B | 20.15 |
| Raia Drogasil SA - (RADLY) | $4.931B | 0.00 | |
| Haemonetics (HAE) | United States | $4.837B | 21.22 |
| BillionToOne (BLLN) | United States | $4.757B | 144.03 |
| DiaSorin S.p.A (DSRLF) | Italy | $4.705B | 0.00 |
| Envista Holdings (NVST) | United States | $4.142B | 17.54 |
| ICU Medical (ICUI) | United States | $3.939B | 23.52 |
| AtriCure (ATRC) | United States | $2.838B | 242.57 |
| Neogen (NEOG) | United States | $2.606B | 45.96 |
| Curaleaf Holdings (CURLD) | Canada | $2.388B | 0.00 |
| Curaleaf Holdings (CURLF) | United States | $2.356B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $2.256B | 10.77 |
| Trulieve Cannabis (TRLV) | United States | $2.238B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.207B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.894B | 5.46 |
| LeMaitre Vascular (LMAT) | United States | $1.847B | 29.69 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $1.798B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.736B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.733B | 221.44 |
| Phibro Animal Health (PAHC) | United States | $1.459B | 11.20 |
| Green Thumb Industries (GTBIF) | United States | $1.428B | 15.23 |
| Kestra Medical Technologies (KMTS) | United States | $1.410B | 0.00 |
| Omeros (OMER) | United States | $1.264B | 6.40 |
| Lumexa Imaging Holdings (LMRI) | United States | $1.094B | 0.00 |
| CeriBell (CBLL) | United States | $0.934B | 0.00 |
| InMode (INMD) | Israel | $0.856B | 11.91 |
| AdaptHealth (AHCO) | United States | $0.802B | 16.80 |
| VAREX IMAGING (VREX) | United States | $0.777B | 17.09 |
| QuidelOrtho (QDEL) | United States | $0.763B | 8.24 |
| Glass House Brands (GLAS) | United States | $0.760B | 0.00 |
| Valneva SE (VALN) | France | $0.633B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.582B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.564B | 0.00 |
| Brainsway (BWAY) | Israel | $0.548B | 30.98 |
| Evolus (EOLS) | United States | $0.524B | 0.00 |
| Cerus (CERS) | United States | $0.514B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.512B | 0.00 |
| Vireo Growth (VREOD) | United States | $0.451B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.438B | 0.00 |
| Verano Holdings (VRNOD) | United States | $0.425B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.422B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.395B | 8.28 |
| Cresco Labs (CRLBF) | United States | $0.373B | 0.00 |
| SNDL (SNDL) | Canada | $0.353B | 0.00 |
| Village Farms (VFF) | Canada | $0.347B | 15.78 |
| Viemed Healthcare (VMD) | United States | $0.337B | 24.56 |
| Sanara MedTech (SMTI) | United States | $0.321B | 159.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.294B | 0.00 |
| MacroGenics (MGNX) | United States | $0.268B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.247B | 13.14 |
| High Tide (HITI) | Canada | $0.234B | 52.60 |
| OraSure Technologies (OSUR) | United States | $0.232B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.225B | 21.55 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| TerrAscend (TSNDF) | Canada | $0.205B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.194B | 0.00 |
| Exagen (XGN) | United States | $0.178B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Jin Medical (ZJYL) | China | $0.155B | 0.00 |
| Organigram Global (OGI) | Canada | $0.152B | 0.00 |
| Apyx Medical (APYX) | United States | $0.127B | 0.00 |
| Quanterix (QTRX) | United States | $0.118B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| ImmuCell (ICCC) | United States | $0.088B | 121.38 |
| Accendra Health (ACH) | United States | $0.086B | 4.87 |
| FitLife Brands (FTLF) | United States | $0.086B | 11.30 |
| Jushi Holdings (JUSHF) | United States | $0.083B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| InterCure (INCR) | Israel | $0.058B | 0.00 |
| Hongchang (HCIL) | China | $0.052B | 0.00 |
| Biote (BTMD) | United States | $0.050B | 4.12 |
| Nephros (NEPH) | United States | $0.048B | 40.27 |
| Veru (VERU) | United States | $0.040B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.037B | 17.71 |
| United-Guardian (UG) | United States | $0.033B | 13.26 |
| Rockwell Medical (RMTI) | United States | $0.031B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.022B | 0.00 |
| Modular Medical (MODD) | United States | $0.021B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.019B | 0.00 |
| Bonk (BNKK) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| Agape ATP (ATPC) | $0.002B | 0.00 | |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.000B | 0.00 |
| INLIF (INLF) | China | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |